Quick answer: latest quarter results, by ticker or company name

Reported Q: Q3 2024 Rev YoY: +129.1% EPS YoY: +69.7% Move: -2.78%

VistaGen Therapeutics Inc

VTGN

$0.554 -2.78%

Exchange NASDAQ Sector Healthcare Industry Biotechnology

Q3 2024

Published: Feb 13, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for VTGN

Reported

Report Date

Feb 13, 2024

Quarter Q3 2024

Revenue

411.40K

YoY: +129.1%

EPS

-0.43

YoY: +69.7%

Market Move

-2.78%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $0.41M up 129.1% year-over-year
EPS of $-0.43 increased by 69.7% from previous year
Gross margin of 100.0%
Net income of -6.35M
""We are encouraged that novel, late-stage, neuroscience-derived product candidates have stimulated renewed interest in large-market neuropsychiatry programs with the potential to change lives."" - Shawn Singh

VTGN

VistaGen Therapeutics Inc

Period Q3 2024

Currency USD

Report Type Quarterly Earnings

Generated Mar 30, 2026

Swipe to view all report sections

Executive Summary

In Q3 2024, VistaGen Therapeutics Inc (NASDAQ: VTGN) reported revenues of $411,400, reflecting a robust year-over-year growth of 129.06%, attributed to advancements in their neuroscience pipeline and positive trial results. However, the company reported a net loss of $6.3 million, illustrating the ongoing investment in research and development, with R&D expenses decreased to $4.5 million from $6.9 million in the prior year. This financial performance represents a strategic shift as VistaGen prepares for pivotal Phase 3 clinical trials for their lead product, fasedienol, aimed at tackling social anxiety disorder (SAD). Management emphasized their commitment to redefining treatment paradigms in neuropsychiatry, indicating a potential market entry for their therapies as early as late 2024.

Key Performance Indicators

Revenue

Increasing

411.40K

QoQ: 47.99% | YoY: 129.06%

Gross Profit

Increasing

411.40K

1.00% margin

QoQ: 47.99% | YoY: 129.06%

Operating Income

Increasing

-7.88M

QoQ: -16.28% | YoY: 19.28%

Net Income

Increasing

-6.35M

QoQ: 3.62% | YoY: 34.95%

EPS

Increasing

-0.43

QoQ: 34.85% | YoY: 69.72%

Revenue Trend

Margin Analysis

Financial Highlights

1. Revenue: $411,400 (YoY Growth: 129.06%, QoQ Growth: 47.99%) - driven by advancements in clinical trials.
2. Net Income: -$6.3 million (YoY Improvement: 34.95%, QoQ Change: 3.62%) - showing reduced loss compared to previous periods.
3. Cash Reserves: $126.6 million - positioned for future growth and trial funding.
4. Research and Development Expenses: $4.5 million, down from $6.9 million YoY indicates efficient cost management amidst preparations for PALISADE-3 trials.
5. Current Ratio: 30.76 - Indicates excellent liquidity and ability to meet short-term obligations.
6. EBITDA: -$7.74 million, reflecting ongoing operational losses as the company invests heavily in R&D without current product revenues generating significant returns.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	411.40K	129.06%	47.99%
Gross Profit	411.40K	129.06%	47.99%
Operating Income	-7.88M	19.28%	-16.28%
Net Income	-6.35M	34.95%	3.62%
EPS	-0.43	69.72%	34.85%

Key Financial Ratios

Gross Profit Margin

Weak

1.00%

Gross profit margin is below industry norms, profitability concerns

Operating Profit Margin

Weak

-19.16%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-15.43%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.05%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.05%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

30.76

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.02

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-2.97x

Negative earnings make P/E ratio not meaningful

Price to Book

Undervalued

0.61x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q1 2026	0.24	-0.47	+23.7%	View
Q3 2025	0.23	-0.46	-43.1%	View
Q2 2025	0.18	-0.42	-34.2%	View
Q1 2025	0.08	-0.35	-52.5%	View
Q4 2024	0.20	-0.35	+12.4%	View
Q3 2024	0.41	-0.43	+129.1%	View

VTGN

VistaGen Therapeutics Inc

Q1 2026 Report

VistaGen Therapeutics Inc (VTGN) QQ1 2026 Earnings Analysis: PALISADE Phase III Progress, Open-Label Safety Signals, and Near-Term Catalysts...

Read full report

VTGN

VistaGen Therapeutics Inc

Q3 2025 Report

VistaGen Therapeutics Inc (VTGN) Q3 2025 Financial Results: Navigating Clinical Advancements and Financial Challenges...

Read full report

VTGN

VistaGen Therapeutics Inc

Q2 2025 Report

VistaGen Therapeutics Inc (VTGN) QQ2 2025 Financial Results Report: Navigating Through Growth Challenges...

Read full report

VTGN

VistaGen Therapeutics Inc

Q1 2025 Report

VistaGen Therapeutics Inc (VTGN) Q1 2025 Results Analysis: Progress in Pherine Drug Development and Financial Updates...

Read full report

VTGN

VistaGen Therapeutics Inc

Q4 2024 Report

VistaGen Therapeutics Inc (VTGN) Q4 2024 Financial Results: Strategic Milestones and Challenges in CNS Therapeutics...

Read full report

VistaGen Therapeutics Inc (VTGN) Q3 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More VTGN Quarterly Reports

VTGN

VTGN

VTGN

VTGN

VTGN

Q3 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

VTGN Full Profile

VTGN Financial Statements

Earnings Calendar